UNCY UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics to Present at Upcoming Investor Conferences

Unicycive Therapeutics to Present at Upcoming Investor Conferences

LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences.

Event:   Lytham Partners Spring 2025 Investor Conference

Type:   Fireside Chat

Date/Time:   Thursday, May 29, 2025, at 12:30 p.m. ET

Event:   Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference

Type:   Corporate Presentation with Moderated Q&A

Date/Time:   Wednesday, June 4, 2025, at 1 p.m. ET

A link to the live and archived webcasts may be accessed on the Unicycive website under the Investors section: .

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X. For more information, please visit  and follow us on  and .

Investor Contact:

Kevin Gardner

LifeSci Advisors

Media Contact:

Rachel Visi

Real Chemistry

SOURCE: Unicycive Therapeutics, Inc.



EN
22/05/2025

Underlying

UNCYUNICYCIVE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNICYCIVE THERAPEUTICS INC

 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Present at Upcoming Investor Conferences

Unicycive Therapeutics to Present at Upcoming Investor Conferences LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences. Event:   Lytham Partners Spring 2025 Investor Conference Type:   Fireside ChatDate/Time:   Thursday, May 29, 2025, at 12:30 p.m. ET Event:   Noble Capital Markets 2025 Emerging Growth Virtual Equity Confe...

11h / 49m 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting o...

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The previously announced date of the meeting (June 9, 2025) and location of the meeting (4300 El Camino Real, Suite 210, Los Altos, CA 94022) will not change, but the meeting will be h...

May 21, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces First Quarter 2025 Financial Results ...

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., M...

May 14, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Presents New Patient-Level Data Underscoring Challenges Face...

Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis – Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a patient survey conducted in partnership with the National Kidney Foundation (NKF) showed excessive number and large size of phosphate binder pills to be top b...

April 10, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual H...

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: . To request a 1x1 meeting ...

April 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch